AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that will participate in two upcoming investor conferences.
Details for the presentations are as follows:
Event:
Date and Time: Tuesday, May 21, 2024, at 3:20 PM ET
Event:
Date and Time: Wednesday, May 22, 2024, at 3:40 PM ET
Live webcasts of the presentations will be accessible on the page of the section of the Company’s website, .
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit and connect with the Company on , , and .
Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247